Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 27, 2021updated 07 Jan 2022 7:31am

CanSino’s vaccine shows 96% efficacy against severe Covid-19 in Phase III trial

The Convidecia vaccine had an overall efficacy of 63.7% 14 days following inoculation in trial subjects.

CanSino Biologics (CanSinoBIO) has reported that its recombinant Covid-19 vaccine, Convidecia, demonstrated 96% efficacy in averting severe disease in Phase III clinical trial.

The international, randomised, double-blind, multicentre and placebo-controlled trial enrolled 45,000 adult subjects aged 18 years and above in Argentina, Chile, Mexico, Pakistan and Russia.

Findings showed that one dose of the Adenovirus Type 5 Vector-based vaccine was efficacious and safe.

In addition, the vaccine was found to have 63.7% overall efficacy 14 days following inoculation in subjects, with no vaccine-associated serious side effects observed in the trial.

The trial also met all the primary efficacy goals with an overall efficacy rate of 57.5% 28 days after inoculation and an efficacy rate of 91.7% against severe disease.

The data met the efficacy rate needs of the World Health Organization for Covid-19 shots. Additionally, the study established the safety of Convidecia vaccine for a wide range of age groups above 18 years, including people aged over 60 years.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

CanSinoBIO chairman and CEO Dr Xuefeng YU said: “This represents another milestone and provides further evidence of the strong protection provided by our single-dose vaccine, which is now approved in at least ten markets across multiple continents.

“CanSinoBIO remains committed to our mission of providing affordable, timely and mass immune protection to the global population, and will continue to collaborate with partners in the public and private sectors to improve vaccine access and have more people benefit from our technology breakthroughs.”

In another trial, a booster shot of Convidecia in previously vaccinated people offered a nearly 78-fold rise in neutralising antibody levels 14 days after inoculation.

Furthermore, homologous boosting with Convidecia six months following prime vaccination could lead to a seven-fold rise in the levels of neutralising antibodies, the company stated.

Earlier this month, the company entered a development and commercial supply partnership with Ireland-based firm Aerogen for the inhaled formulation of Convidecia.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy